TKI治疗有或无T790M突变的肺腺癌患者疗效的对照研究

被引：1

作者：

马胜林 ^{[1
]}

殷靖宜 ^{[2
,3
,4
]}

机构：

[1] 杭州市第一人民医院

[2] 广东省人民医院肿瘤中心

[3] 广东省医学科学院

[4] 广东省肺癌研究所

来源：

循证医学 | 2013年 / 13卷 / 01期

关键词：

肺腺癌; 酪氨酸激酶抑制剂; T790M突变;

D O I：

暂无

中图分类号：

R734.2 [肺肿瘤];

学科分类号：

100117 [系统生物医学];

摘要：

<正>1文献来源Oxnard GR, Arcila ME, Sima CS, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation [J]. Clin Cancer Res, 2011,17(6):1616-1622. 2证据水平

引用

页码：34 / 36

页数：3

共 3 条

[1]

Highly Sensitive Detection of EGFR T790M Mutation Using Colony Hybridization Predicts Favorable Prognosis of Patients with Lung Cancer Harboring Activating EGFR Mutation [J].

Fujita, Yoshihiko ;

Suda, Kenichi ;

Kimura, Hideharu ;

Matsumoto, Kazuko ;

Arao, Tokuzo ;

Nagai, Tomoyuki ;

Saijo, Nagahiro ;

Yatabe, Yasushi ;

Mitsudomi, Tetsuya ;

Nishio, Kazuto .

JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) :1640-1644

[2]

Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial [J].

Jaenne, Pasi A. ;

Wang, Xiaofei ;

Socinski, Mark A. ;

Crawford, Jeffrey ;

Stinchcombe, Thomas E. ;

Gu, Lin ;

Capelletti, Marzia ;

Edelman, Martin J. ;

Villalona-Calero, Miguel A. ;

Kratzke, Robert ;

Vokes, Everett E. ;

Miller, Vincent A. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2063-2069

[3]

EGFR T790M decreases growth potential of lung tumor cells with drug-sensitive EGFR mutant alleles in the absence of drug selection..Chmielecki J;Foo J;Somwar R;Regales L;Vivanco I;Shen RL;et al;.American Associa-tion for Cancer Research Annual Meeting:Proceedings.2009,

← 1 →